{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T15:14:40Z","timestamp":1792682080727,"version":"4.5.0"},"reference-count":101,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T00:00:00Z","timestamp":1748995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T00:00:00Z","timestamp":1748995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurobiol"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s12035-025-05097-9","type":"journal-article","created":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T19:09:45Z","timestamp":1748977785000},"page":"15070-15092","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Psychedelics in the Treatment of Neurologic and Psychiatric Disorders: Coincidence or a New Point of View"],"prefix":"10.1007","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0502-6114","authenticated-orcid":false,"given":"Naser-Aldin","family":"Lashgari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahla","family":"Khalaji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pouria","family":"Rana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Badrabadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mobina","family":"Rahnama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadis","family":"Nasoori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazanin","family":"Momeni Roudsari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Mahdi","family":"Khosravi Nia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamed","family":"Shafaroodi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,4]]},"reference":[{"issue":"4","key":"5097_CR1","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1172\/JCI95145","volume":"128","author":"DJ Baker","year":"2018","unstructured":"Baker DJ, Petersen RC (2018) Cellular senescence in brain aging and neurodegenerative diseases: evidence and perspectives. J Clin Invest 128(4):1208\u20131216","journal-title":"J Clin Invest"},{"issue":"4","key":"5097_CR2","doi-asserted-by":"publisher","first-page":"a033118","DOI":"10.1101\/cshperspect.a033118","volume":"10","author":"MG Erkkinen","year":"2018","unstructured":"Erkkinen MG, Kim MO, Geschwind MD (2018) Clinical neurology and epidemiology of the major neurodegenerative diseases. Cold Spring Harb Perspect Biol 10(4):a033118","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"5097_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2021.577758","volume":"361","author":"N-A Lashgari","year":"2021","unstructured":"Lashgari N-A et al (2021) The involvement of JAK\/STAT signaling pathway in the treatment of Parkinson\u2019s disease. J Neuroimmunol 361:577758","journal-title":"J Neuroimmunol"},{"key":"5097_CR4","doi-asserted-by":"crossref","unstructured":"Lashgari N-A, et al. (2024) LRRK2; communicative role in the treatment of Parkinson\u2019s disease and ulcerative colitis overlapping. CNS Neurol Disord Drug Targets 23(10):1177\u20131188","DOI":"10.2174\/0118715273270874231205050727"},{"issue":"3","key":"5097_CR5","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1139\/cjpp-2023-0107","volume":"102","author":"N-A Lashgari","year":"2023","unstructured":"Lashgari N-A et al (2023) TLR\/mTOR inflammatory signaling pathway: novel insight for the treatment of schizophrenia. Can J Physiol Pharmacol 102(3):150\u2013160","journal-title":"Can J Physiol Pharmacol"},{"issue":"12","key":"5097_CR6","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.2174\/0929867330666230213114909","volume":"31","author":"N-A Lashgari","year":"2024","unstructured":"Lashgari N-A et al (2024) Spinal muscular atrophy treatment: the MTOR regulatory intervention. Curr Med Chem 31(12):1512\u20131522","journal-title":"Curr Med Chem"},{"issue":"5","key":"5097_CR7","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/S1474-4422(19)30029-8","volume":"18","author":"WM Carroll","year":"2019","unstructured":"Carroll WM (2019) The global burden of neurological disorders. Lancet Neurol 18(5):418\u2013419","journal-title":"Lancet Neurol"},{"key":"5097_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/01.NT.0000521169.52982.7f","volume":"17","author":"G Shaw","year":"2017","unstructured":"Shaw G (2017) The economic burden of neurologic disease \u2014 $800 billion annually in the US. Neurol Today 17:1","journal-title":"Neurol Today"},{"key":"5097_CR9","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.clnesp.2021.05.028","volume":"44","author":"B Blanco","year":"2021","unstructured":"Blanco B, Mora T, Trapero-Bertran M (2021) Direct health care costs associated to neurological diseases and different degrees of malnutrition. Clinical Nutrition ESPEN 44:297\u2013305","journal-title":"Clin Nutr ESPEN"},{"issue":"16","key":"5097_CR10","doi-asserted-by":"publisher","first-page":"8654","DOI":"10.3390\/ijms22168654","volume":"22","author":"YJ Cheng","year":"2021","unstructured":"Cheng YJ, Lin CH, Lane HY (2021) From menopause to neurodegeneration-molecular basis and potential therapy. Int J Mol Sci 22(16):8654","journal-title":"Int J Mol Sci"},{"issue":"4","key":"5097_CR11","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1159\/000381546","volume":"1","author":"X Chen","year":"2015","unstructured":"Chen X, Pan W (2015) The treatment strategies for neurodegenerative diseases by integrative medicine. Integr Med Int 1(4):223\u2013225","journal-title":"Integr Med Int"},{"key":"5097_CR12","doi-asserted-by":"publisher","first-page":"213","DOI":"10.3389\/fnins.2020.00213","volume":"14","author":"VR Muddapu","year":"2020","unstructured":"Muddapu VR et al (2020) Neurodegenerative diseases\u2013is metabolic deficiency the root cause? Front Neurosci 14:213","journal-title":"Front Neurosci"},{"issue":"9","key":"5097_CR13","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1056\/NEJMoa044397","volume":"354","author":"H Polman Chris","year":"2006","unstructured":"Polman Chris H et al (2006) A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354(9):899\u2013910","journal-title":"N Engl J Med"},{"issue":"1","key":"5097_CR14","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1111\/jnc.15544","volume":"162","author":"HN Saeger","year":"2022","unstructured":"Saeger HN, Olson DE (2022) Psychedelic-inspired approaches for treating neurodegenerative disorders. J Neurochem 162(1):109\u2013127","journal-title":"J Neurochem"},{"key":"5097_CR15","doi-asserted-by":"publisher","first-page":"727117","DOI":"10.3389\/fpsyt.2021.727117","volume":"12","author":"M Vargas","year":"2021","unstructured":"Vargas M et al (2021) Psychedelics and other psychoplastogens for treating mental illness. Front Psychiatry 12:727117","journal-title":"Front Psychiatry"},{"issue":"3","key":"5097_CR16","first-page":"279","volume":"7","author":"SW Wheeler","year":"2020","unstructured":"Wheeler SW, Dyer NL (2020) A systematic review of psychedelic-assisted psychotherapy for mental health: an evaluation of the current wave of research and suggestions for the future. Psychol Conscious Theory Res Pract 7(3):279","journal-title":"Psychol Conscious Theory Res Pract"},{"key":"5097_CR17","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1007\/s40263-020-00748-y","volume":"34","author":"JJ Breeksema","year":"2020","unstructured":"Breeksema JJ et al (2020) Psychedelic treatments for psychiatric disorders: a systematic review and thematic synthesis of patient experiences in qualitative studies. CNS Drugs 34:925\u2013946","journal-title":"CNS Drugs"},{"key":"5097_CR18","doi-asserted-by":"publisher","first-page":"965","DOI":"10.2147\/JPR.S439348","volume":"17","author":"CL Robinson","year":"2024","unstructured":"Robinson CL et al (2024) Scoping review: the role of psychedelics in the management of chronic pain. J Pain Res 17:965\u2013973","journal-title":"J Pain Res"},{"issue":"3","key":"5097_CR19","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1521\/pdps.2023.51.3.270","volume":"51","author":"T Lindegaard","year":"2023","unstructured":"Lindegaard T (2023) Do psychedelics facilitate emergence of unconscious psychological processes? Psychodyn Psychiatry 51(3):270\u2013286","journal-title":"Psychodyn Psychiatry"},{"issue":"6","key":"5097_CR20","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.688","volume":"8","author":"B Stewart","year":"2020","unstructured":"Stewart B et al (2020) Psychedelic-assisted therapy for functional neurological disorders: a theoretical framework and review of prior reports. Pharmacol Res Perspect 8(6):e00688","journal-title":"Pharmacol Res Perspect"},{"key":"5097_CR21","doi-asserted-by":"publisher","first-page":"204512532091212","DOI":"10.1177\/2045125320912125","volume":"10","author":"M Butler","year":"2020","unstructured":"Butler M et al (2020) Psychedelic treatment of functional neurological disorder: a systematic review. Ther Adv Psychopharmacol 10:2045125320912125","journal-title":"Ther Adv Psychopharmacol"},{"key":"5097_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2025.111278","volume":"137","author":"JL de Deus","year":"2025","unstructured":"de Deus JL et al (2025) Psychedelics in neuroinflammation: mechanisms and therapeutic potential. Prog Neuropsychopharmacol Biol Psychiatry 137:111278","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"4","key":"5097_CR23","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1080\/09540261.2018.1481827","volume":"30","author":"TW Flanagan","year":"2018","unstructured":"Flanagan TW, Nichols CD (2018) Psychedelics as anti-inflammatory agents. Int Rev Psychiatry 30(4):363\u2013375","journal-title":"Int Rev Psychiatry"},{"key":"5097_CR24","doi-asserted-by":"crossref","unstructured":"Canal CE (2018) Serotonergic psychedelics: experimental approaches for assessing mechanisms of action. In: New Psychoactive Substances: Pharmacology, Clinical, Forensic and Analytical Toxicology, pp 227\u2013260","DOI":"10.1007\/164_2018_107"},{"key":"5097_CR25","doi-asserted-by":"publisher","first-page":"1076459","DOI":"10.3389\/fpsyt.2022.1076459","volume":"13","author":"MI Husain","year":"2023","unstructured":"Husain MI et al (2023) Serotonergic psychedelics for depression: what do we know about neurobiological mechanisms of action? Front Psych 13:1076459","journal-title":"Front Psych"},{"key":"5097_CR26","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/bs.pbr.2018.07.008","volume":"242","author":"D De Gregorio","year":"2018","unstructured":"De Gregorio D et al (2018) D-lysergic acid diethylamide, psilocybin, and other classic hallucinogens: mechanism of action and potential therapeutic applications in mood disorders. Prog Brain Res 242:69\u201396","journal-title":"Prog Brain Res"},{"key":"5097_CR27","doi-asserted-by":"crossref","unstructured":"Szpr\u0119giel I, Bysiek A (2024) Psilocybin and the glutamatergic pathway: implications for the treatment of neuropsychiatric diseases. Pharmacol Rep 1\u20138","DOI":"10.1007\/s43440-024-00660-y"},{"issue":"6","key":"5097_CR28","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1038\/s41593-023-01316-5","volume":"26","author":"R Moliner","year":"2023","unstructured":"Moliner R et al (2023) Psychedelics promote plasticity by directly binding to BDNF receptor TrkB. Nat Neurosci 26(6):1032\u20131041","journal-title":"Nat Neurosci"},{"issue":"1","key":"5097_CR29","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41386-023-01666-5","volume":"49","author":"BD Heifets","year":"2024","unstructured":"Heifets BD, Olson DE (2024) Therapeutic mechanisms of psychedelics and entactogens. Neuropsychopharmacology 49(1):104\u2013118","journal-title":"Neuropsychopharmacology"},{"key":"5097_CR30","doi-asserted-by":"crossref","unstructured":"Butler JJ, Ricci D, Aman C, Beyeler A, De Deurwaerd\u00e8re P (2024) Classical psychedelics\u2019 action on brain monoaminergic systems. Int J Biochem Cell Biol 106669","DOI":"10.1016\/j.biocel.2024.106669"},{"issue":"3","key":"5097_CR31","doi-asserted-by":"publisher","first-page":"248","DOI":"10.3390\/brainsci14030248","volume":"14","author":"MR Velit-Salazar","year":"2024","unstructured":"Velit-Salazar MR, Shiroma PR, Cherian E (2024) A systematic review of the neurocognitive effects of psychedelics in healthy populations: implications for depressive disorders and post-traumatic stress disorder. Brain Sci 14(3):248","journal-title":"Brain Sci"},{"issue":"6","key":"5097_CR32","doi-asserted-by":"publisher","first-page":"708","DOI":"10.3390\/pharmaceutics16060708","volume":"16","author":"L Sequeira","year":"2024","unstructured":"Sequeira L et al (2024) Drug development for Alzheimer\u2019s and Parkinson\u2019s disease: where do we go now? Pharmaceutics 16(6):708","journal-title":"Pharmaceutics"},{"issue":"5","key":"5097_CR33","doi-asserted-by":"publisher","first-page":"640","DOI":"10.3390\/ph15050640","volume":"15","author":"D Mahmood","year":"2022","unstructured":"Mahmood D et al (2022) New paradigms of old psychedelics in schizophrenia. Pharmaceuticals 15(5):640","journal-title":"Pharmaceuticals"},{"issue":"12","key":"5097_CR34","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1177\/0269881116675512","volume":"30","author":"S Ross","year":"2016","unstructured":"Ross S et al (2016) Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. J Psychopharmacol 30(12):1165\u20131180","journal-title":"J Psychopharmacol"},{"issue":"18","key":"5097_CR35","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1056\/NEJMoa2206443","volume":"387","author":"GM Goodwin","year":"2022","unstructured":"Goodwin GM et al (2022) Single-dose psilocybin for a treatment-resistant episode of major depression. N Engl J Med 387(18):1637\u20131648","journal-title":"N Engl J Med"},{"issue":"7","key":"5097_CR36","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/S2215-0366(16)30065-7","volume":"3","author":"RL Carhart-Harris","year":"2016","unstructured":"Carhart-Harris RL et al (2016) Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. The Lancet Psychiatry 3(7):619\u2013627","journal-title":"The Lancet Psychiatry"},{"issue":"D1","key":"5097_CR37","doi-asserted-by":"publisher","first-page":"D1138","DOI":"10.1093\/nar\/gkaa891","volume":"49","author":"AP Davis","year":"2021","unstructured":"Davis AP et al (2021) Comparative toxicogenomics database (CTD): update 2021. Nucleic Acids Res 49(D1):D1138\u2013D1143","journal-title":"Nucleic Acids Res"},{"issue":"15","key":"5097_CR38","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1056\/NEJMoa2032994","volume":"384","author":"R Carhart-Harris","year":"2021","unstructured":"Carhart-Harris R et al (2021) Trial of psilocybin versus escitalopram for depression. N Engl J Med 384(15):1402\u20131411","journal-title":"N Engl J Med"},{"issue":"7","key":"5097_CR39","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1177\/02698811231154852","volume":"37","author":"J Sloshower","year":"2023","unstructured":"Sloshower J et al (2023) Psilocybin-assisted therapy for major depressive disorder: an exploratory placebo-controlled, fixed-order trial. J Psychopharmacol 37(7):698\u2013706","journal-title":"J Psychopharmacol"},{"issue":"4","key":"5097_CR40","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1017\/S0033291718001356","volume":"49","author":"F Palhano-Fontes","year":"2019","unstructured":"Palhano-Fontes F et al (2019) Rapid antidepressant effects of the psychedelic Ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial. Psychol Med 49(4):655\u2013663","journal-title":"Psychol Med"},{"issue":"1","key":"5097_CR41","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1097\/JCP.0000000000000436","volume":"36","author":"RF Sanches","year":"2016","unstructured":"Sanches RF et al (2016) Antidepressant effects of a single dose of Ayahuasca in patients with recurrent depression: a SPECT study. J Clin Psychopharmacol 36(1):77\u201381","journal-title":"J Clin Psychopharmacol"},{"issue":"3","key":"5097_CR42","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.biopsych.2022.08.025","volume":"93","author":"F Holze","year":"2023","unstructured":"Holze F et al (2023) Lysergic acid diethylamide\u2013assisted therapy in patients with anxiety with and without a life-threatening illness: a randomized, double-blind, placebo-controlled phase II study. Biol Psychiat 93(3):215\u2013223","journal-title":"Biol Psychiat"},{"issue":"1","key":"5097_CR43","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1001\/archgenpsychiatry.2010.116","volume":"68","author":"CS Grob","year":"2011","unstructured":"Grob CS et al (2011) Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Arch Gen Psychiatry 68(1):71\u201378","journal-title":"Arch Gen Psychiatry"},{"issue":"2","key":"5097_CR44","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41573-020-0090-8","volume":"20","author":"MJ Mitchell","year":"2021","unstructured":"Mitchell MJ et al (2021) Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov 20(2):101\u2013124","journal-title":"Nat Rev Drug Discov"},{"key":"5097_CR45","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s00213-020-05692-9","volume":"238","author":"RJ Zeifman","year":"2021","unstructured":"Zeifman RJ et al (2021) Rapid and sustained decreases in suicidality following a single dose of Ayahuasca among individuals with recurrent major depressive disorder: results from an open-label trial. Psychopharmacology 238:453\u2013459","journal-title":"Psychopharmacology"},{"issue":"5","key":"5097_CR46","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1001\/jamapsychiatry.2020.3285","volume":"78","author":"AK Davis","year":"2021","unstructured":"Davis AK et al (2021) Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial. JAMA Psychiat 78(5):481\u2013489","journal-title":"JAMA Psychiat"},{"issue":"6","key":"5097_CR47","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1038\/s41591-021-01336-3","volume":"27","author":"JM Mitchell","year":"2021","unstructured":"Mitchell JM et al (2021) MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nat Med 27(6):1025\u20131033","journal-title":"Nat Med"},{"issue":"8","key":"5097_CR48","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1038\/sj.mp.4001093","volume":"7","author":"S Kapur","year":"2002","unstructured":"Kapur S, Seeman P (2002) NMDA receptor antagonists ketamine and PCP have direct effects on the dopamine D(2) and serotonin 5-HT(2)receptors-implications for models of schizophrenia. Mol Psychiatry 7(8):837\u2013844","journal-title":"Mol Psychiatry"},{"key":"5097_CR49","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.bcp.2016.09.006","volume":"120","author":"NR Sealover","year":"2016","unstructured":"Sealover NR et al (2016) The external gate of the human and Drosophila serotonin transporters requires a basic\/acidic amino acid pair for 3,4-methylenedioxymethamphetamine (MDMA) translocation and the induction of substrate efflux. Biochem Pharmacol 120:46\u201355","journal-title":"Biochem Pharmacol"},{"issue":"12","key":"5097_CR50","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1007\/s00702-009-0308-8","volume":"116","author":"NV Cozzi","year":"2009","unstructured":"Cozzi NV et al (2009) Dimethyltryptamine and other hallucinogenic tryptamines exhibit substrate behavior at the serotonin uptake transporter and the vesicle monoamine transporter. J Neural Transm (Vienna) 116(12):1591\u20131599","journal-title":"J Neural Transm (Vienna)"},{"issue":"6","key":"5097_CR51","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1007\/s00702-017-1706-y","volume":"124","author":"Z Marinova","year":"2017","unstructured":"Marinova Z, Walitza S, Gr\u00fcnblatt E (2017) The hallucinogen 2,5-dimethoxy-4-iodoamphetamine hydrochloride activates neurotrophin receptors in a neuronal cell line and promotes neurites extension. J Neural Transm (Vienna) 124(6):749\u2013759","journal-title":"J Neural Transm (Vienna)"},{"issue":"9","key":"5097_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2015.136","volume":"5","author":"C Yang","year":"2015","unstructured":"Yang C et al (2015) R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects. Transl Psychiatry 5(9):e632","journal-title":"Transl Psychiatry"},{"issue":"4","key":"5097_CR53","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/0192-0561(88)90137-3","volume":"10","author":"Y Kawakami","year":"1988","unstructured":"Kawakami Y et al (1988) Suppression by delta-9-tetrahydrocannabinol of interleukin 2-induced lymphocyte proliferation and lymphokine-activated killer cell activity. Int J Immunopharmacol 10(4):485\u2013488","journal-title":"Int J Immunopharmacol"},{"key":"5097_CR54","doi-asserted-by":"crossref","unstructured":"Eshleman AJ, Forster MJ, Wolfrum KM, Johnson RA, Janowsky A, Gatch MB (2014) Behavioral and neurochemical pharmacology of six psychoactive substituted phenethylamines: mouse locomotion, rat drug discrimination and in vitro receptor and transporter binding and function. Psychopharmacol 231:875\u2013888","DOI":"10.1007\/s00213-013-3303-6"},{"issue":"1\u20132","key":"5097_CR55","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/0006-8993(95)00201-Z","volume":"680","author":"JC Poblete","year":"1995","unstructured":"Poblete JC, Azmitia EC (1995) Activation of glycogen phosphorylase by serotonin and 3,4-methylenedioxymethamphetamine in astroglial-rich primary cultures: involvement of the 5-HT2A receptor. Brain Res 680(1\u20132):9\u201315","journal-title":"Brain Res"},{"issue":"7","key":"5097_CR56","doi-asserted-by":"publisher","first-page":"3261","DOI":"10.1021\/acschemneuro.8b00692","volume":"10","author":"LP Cameron","year":"2019","unstructured":"Cameron LP et al (2019) Chronic, intermittent microdoses of the psychedelic N, N-dimethyltryptamine (DMT) produce positive effects on mood and anxiety in rodents. ACS Chem Neurosci 10(7):3261\u20133270","journal-title":"ACS Chem Neurosci"},{"issue":"S1","key":"5097_CR57","doi-asserted-by":"publisher","first-page":"666.1","DOI":"10.1096\/fasebj.2019.33.1_supplement.666.1","volume":"33","author":"M Hibicke","year":"2019","unstructured":"Hibicke M et al (2019) Psychedelics improve the mental health of rats. FASEB J 33(S1):666.1","journal-title":"FASEB J"},{"issue":"11","key":"5097_CR58","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1021\/acschemneuro.0c00152","volume":"11","author":"P Rodr\u0131 Guez","year":"2020","unstructured":"Rodr\u0131 Guez P et al (2020) A single administration of the atypical psychedelic ibogaine or its metabolite noribogaine induces an antidepressant-like effect in rats. ACS Chem Neurosci 11(11):1661\u20131672","journal-title":"ACS Chem Neurosci"},{"key":"5097_CR59","doi-asserted-by":"crossref","unstructured":"Kolasa M, et al (2024)\u00a0 Unraveling psilocybin\u2019s therapeutic potential: behavioral and neuroplasticity insights in Wistar-Kyoto and Wistar male rat models of treatment-resistant depression. Psychopharmacology (Berl)","DOI":"10.1007\/s00213-024-06644-3"},{"issue":"3","key":"5097_CR60","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1021\/acschemneuro.2c00718","volume":"14","author":"LP Cameron","year":"2023","unstructured":"Cameron LP et al (2023) 5-HT2ARs Mediate therapeutic behavioral effects of psychedelic tryptamines. ACS Chem Neurosci 14(3):351\u2013358","journal-title":"ACS Chem Neurosci"},{"issue":"7","key":"5097_CR61","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1038\/s41386-023-01545-z","volume":"48","author":"A Torrado Pacheco","year":"2023","unstructured":"Torrado Pacheco A et al (2023) Acute psilocybin enhances cognitive flexibility in rats. Neuropsychopharmacology 48(7):1011\u20131020","journal-title":"Neuropsychopharmacology"},{"key":"5097_CR62","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.640241","volume":"12","author":"GA Higgins","year":"2021","unstructured":"Higgins GA et al (2021) Low doses of psilocybin and ketamine enhance motivation and attention in poor performing rats: evidence for an antidepressant property. Front Pharmacol 12:640241","journal-title":"Front Pharmacol"},{"issue":"1","key":"5097_CR63","doi-asserted-by":"publisher","first-page":"100","DOI":"10.3390\/ijms25010100","volume":"25","author":"A Wojtas","year":"2023","unstructured":"Wojtas A et al (2023) Limbic system response to psilocybin and ketamine administration in rats: a neurochemical and behavioral study. Int J Mol Sci 25(1):100","journal-title":"Int J Mol Sci"},{"issue":"6","key":"5097_CR64","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1177\/0269881114531666","volume":"28","author":"T Buchborn","year":"2014","unstructured":"Buchborn T et al (2014) Repeated lysergic acid diethylamide in an animal model of depression: normalisation of learning behaviour and hippocampal serotonin 5-HT2 signalling. J Psychopharmacol 28(6):545\u2013552","journal-title":"J Psychopharmacol"},{"issue":"4","key":"5097_CR65","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1017\/neu.2019.15","volume":"31","author":"O Jefsen","year":"2019","unstructured":"Jefsen O et al (2019) Psilocybin lacks antidepressant-like effect in the flinders sensitive line rat. Acta Neuropsychiatr 31(4):213\u2013219","journal-title":"Acta Neuropsychiatr"},{"key":"5097_CR66","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.bbr.2015.08.018","volume":"296","author":"EJ Kyzar","year":"2016","unstructured":"Kyzar EJ, Stewart AM, Kalueff AV (2016) Effects of LSD on grooming behavior in serotonin transporter heterozygous (Sert\u207a\/\u207b) mice. Behav Brain Res 296:47\u201352","journal-title":"Behav Brain Res"},{"issue":"12","key":"5097_CR67","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0145840","volume":"10","author":"VM Favaro","year":"2015","unstructured":"Favaro VM et al (2015) Effects of long-term Ayahuasca administration on memory and anxiety in rats. PLoS ONE 10(12):e0145840","journal-title":"PLoS ONE"},{"key":"5097_CR68","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2023.175926","volume":"955","author":"BG Ferri","year":"2023","unstructured":"Ferri BG et al (2023) Psychoactive substances 25H-NBOMe and 25H-NBOH induce antidepressant-like behavior in male rats. Eur J Pharmacol 955:175926","journal-title":"Eur J Pharmacol"},{"issue":"17","key":"5097_CR69","doi-asserted-by":"publisher","first-page":"e2022489118","DOI":"10.1073\/pnas.2022489118","volume":"118","author":"N Hesselgrave","year":"2021","unstructured":"Hesselgrave N et al (2021) Harnessing psilocybin: antidepressant-like behavioral and synaptic actions of psilocybin are independent of 5-HT2R activation in mice. Proc Natl Acad Sci U S A 118(17):e2022489118","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"5097_CR70","doi-asserted-by":"publisher","first-page":"3829","DOI":"10.1038\/s41380-023-02280-z","volume":"28","author":"KF Kiilerich","year":"2023","unstructured":"Kiilerich KF et al (2023) Repeated low doses of psilocybin increase resilience to stress, lower compulsive actions, and strengthen cortical connections to the paraventricular thalamic nucleus in rats. Mol Psychiatry 28(9):3829\u20133841","journal-title":"Mol Psychiatry"},{"key":"5097_CR71","doi-asserted-by":"crossref","unstructured":"Broadbear JH, Tunstall B, Beringer K (2011) Examining the role of oxytocin in the interoceptive effects of 3, 4\u2010 methylenedioxymethamphetamine (MDMA,\u2018ecstasy\u2019) using a drug discrimination paradigm in the rat. Addict Biol 16(2):202\u2013214","DOI":"10.1111\/j.1369-1600.2010.00267.x"},{"issue":"7","key":"5097_CR72","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1021\/acschemneuro.8b00134","volume":"9","author":"LP Cameron","year":"2018","unstructured":"Cameron LP et al (2018) Effects of N, N-dimethyltryptamine on rat behaviors relevant to anxiety and depression. ACS Chem Neurosci 9(7):1582\u20131590","journal-title":"ACS Chem Neurosci"},{"key":"5097_CR73","doi-asserted-by":"publisher","first-page":"1183740","DOI":"10.3389\/fpsyt.2023.1183740","volume":"14","author":"R Zafar","year":"2023","unstructured":"Zafar R et al (2023) Psychedelic therapy in the treatment of addiction: the past, present and future. Front Psychiatry 14:1183740","journal-title":"Front Psychiatry"},{"issue":"3","key":"5097_CR74","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1007\/s00213-006-0457-5","volume":"187","author":"RR Griffiths","year":"2006","unstructured":"Griffiths RR et al (2006) Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology (Berl) 187(3):268\u201383 (discussion 284\u201392)","journal-title":"Psychopharmacology (Berl)"},{"issue":"11","key":"5097_CR75","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1038\/npp.2017.84","volume":"42","author":"RL Carhart-Harris","year":"2017","unstructured":"Carhart-Harris RL, Goodwin GM (2017) The therapeutic potential of psychedelic drugs: past, present, and future. Neuropsychopharmacology 42(11):2105\u20132113","journal-title":"Neuropsychopharmacology"},{"issue":"7","key":"5097_CR76","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a028035","volume":"9","author":"BN Dugger","year":"2017","unstructured":"Dugger BN, Dickson DW (2017) Pathology of neurodegenerative diseases. Cold Spring Harb Perspect Biol 9(7):a028035","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"5097_CR77","unstructured":"(2019) Global, regional, and national burden of neurological disorders, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 18(5):459\u2013480"},{"key":"5097_CR78","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101580","volume":"51","author":"A Nandi","year":"2022","unstructured":"Nandi A et al (2022) Global and regional projections of the economic burden of Alzheimer\u2019s disease and related dementias from 2019 to 2050: a value of statistical life approach. EClinicalMedicine 51:101580","journal-title":"EClinicalMedicine"},{"issue":"2","key":"5097_CR79","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.euroneuro.2010.08.002","volume":"21","author":"S von Campenhausen","year":"2011","unstructured":"von Campenhausen S et al (2011) Costs of illness and care in Parkinson\u2019s disease: an evaluation in six countries. Eur Neuropsychopharmacol 21(2):180\u2013191","journal-title":"Eur Neuropsychopharmacol"},{"key":"5097_CR80","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/978-981-13-9431-7_17","volume-title":"Bioeconomy for Sustainable Development","author":"W Zahra","year":"2020","unstructured":"Zahra W et al (2020) The global economic impact of neurodegenerative diseases: opportunities and challenges. In: Keswani C (ed) Bioeconomy for Sustainable Development. Springer Singapore, Singapore, pp 333\u2013345"},{"issue":"6","key":"5097_CR81","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1097\/JCP.0000000000001608","volume":"42","author":"N Ledwos","year":"2022","unstructured":"Ledwos N et al (2022) A critical appraisal of evidence on the efficacy and safety of serotonergic psychedelic drugs as emerging antidepressants: mind the evidence gap. J Clin Psychopharmacol 42(6):581\u2013588","journal-title":"J Clin Psychopharmacol"},{"key":"5097_CR82","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.jad.2022.09.168","volume":"322","author":"K Ko","year":"2023","unstructured":"Ko K et al (2023) Psychedelic therapy for depressive symptoms: a systematic review and meta-analysis. J Affect Disord 322:194\u2013204","journal-title":"J Affect Disord"},{"key":"5097_CR83","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.exer.2015.07.022","volume":"140","author":"MR Biswal","year":"2015","unstructured":"Biswal MR et al (2015) Systemic treatment with a 5HT1a agonist induces anti-oxidant protection and preserves the retina from mitochondrial oxidative stress. Exp Eye Res 140:94\u2013105","journal-title":"Exp Eye Res"},{"issue":"6","key":"5097_CR84","first-page":"4774","volume":"20","author":"J Mao","year":"2019","unstructured":"Mao J et al (2019) Role of endoplasmic reticulum stress in depression. Mol Med Rep 20(6):4774\u20134780","journal-title":"Mol Med Rep"},{"key":"5097_CR85","doi-asserted-by":"publisher","first-page":"346","DOI":"10.3389\/fphar.2018.00346","volume":"9","author":"S-P Li","year":"2018","unstructured":"Li S-P et al (2018) Analogous \u03b2-carboline alkaloids harmaline and harmine ameliorate scopolamine-induced cognition dysfunction by attenuating acetylcholinesterase activity, oxidative stress, and inflammation in mice. Front Pharmacol 9:346","journal-title":"Front Pharmacol"},{"issue":"10","key":"5097_CR86","doi-asserted-by":"publisher","first-page":"9041","DOI":"10.18632\/aging.103166","volume":"12","author":"L Jiang","year":"2020","unstructured":"Jiang L et al (2020) Sigma-1 receptor is involved in diminished ovarian reserve possibly by influencing endoplasmic reticulum stress-mediated granulosa cells apoptosis. Aging (Albany NY) 12(10):9041","journal-title":"Aging (Albany NY)"},{"key":"5097_CR87","doi-asserted-by":"publisher","unstructured":"Ryskamp D, et al (2019) Receptors: signaling functions and protective roles in neurodegenerative diseases, 13:862. https:\/\/doi.org\/10.3389\/fnins","DOI":"10.3389\/fnins"},{"issue":"3","key":"5097_CR88","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1111\/imm.12163","volume":"141","author":"L Peferoen","year":"2014","unstructured":"Peferoen L et al (2014) Oligodendrocyte-microglia cross-talk in the central nervous system. Immunology 141(3):302\u2013313","journal-title":"Immunology"},{"issue":"2","key":"5097_CR89","doi-asserted-by":"publisher","first-page":"408","DOI":"10.3390\/antiox11020408","volume":"11","author":"A Ashok","year":"2022","unstructured":"Ashok A et al (2022) Antioxidant therapy in oxidative stress-induced neurodegenerative diseases: role of nanoparticle-based drug delivery systems in clinical translation. Antioxidants (Basel) 11(2):408","journal-title":"Antioxidants (Basel)"},{"key":"5097_CR90","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2024.111155","volume":"136","author":"RD Ordovich-Clarkson","year":"2025","unstructured":"Ordovich-Clarkson RD et al (2025) Comparing psilocybin to metformin as neuroprotective agents against Parkinson\u2019s dementia: a systematic review of evidence and efficacy. Prog Neuropsychopharmacol Biol Psychiatry 136:111155","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"10","key":"5097_CR91","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1016\/j.cellsig.2010.03.019","volume":"22","author":"AM Polter","year":"2010","unstructured":"Polter AM, Li X (2010) 5-HT1A receptor-regulated signal transduction pathways in brain. Cell Signal 22(10):1406\u20131412","journal-title":"Cell Signal"},{"key":"5097_CR92","doi-asserted-by":"publisher","first-page":"116","DOI":"10.3389\/fnmol.2020.00116","volume":"13","author":"MA Hannan","year":"2020","unstructured":"Hannan MA et al (2020) Neuroprotection against oxidative stress: phytochemicals targeting TrkB signaling and the Nrf2-ARE antioxidant system. Front Mol Neurosci 13:116","journal-title":"Front Mol Neurosci"},{"issue":"3","key":"5097_CR93","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/s41380-023-02360-0","volume":"29","author":"J Allen","year":"2024","unstructured":"Allen J et al (2024) Psychedelics for acquired brain injury: a review of molecular mechanisms and therapeutic potential. Mol Psychiatry 29(3):671\u2013685","journal-title":"Mol Psychiatry"},{"key":"5097_CR94","doi-asserted-by":"publisher","first-page":"121","DOI":"10.3389\/fphar.2012.00121","volume":"3","author":"SM Kousik","year":"2012","unstructured":"Kousik SM, Napier TC, Carvey PM (2012) The effects of psychostimulant drugs on blood brain barrier function and neuroinflammation. Front Pharmacol 3:121","journal-title":"Front Pharmacol"},{"issue":"1","key":"5097_CR95","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s13195-024-01462-3","volume":"16","author":"D Cheng","year":"2024","unstructured":"Cheng D et al (2024) N, N-Dimethyltryptamine, a natural hallucinogen, ameliorates Alzheimer\u2019s disease by restoring neuronal sigma-1 receptor-mediated endoplasmic reticulum-mitochondria crosstalk. Alzheimers Res Ther 16(1):95","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"5097_CR96","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1017\/S1092852920001765","volume":"27","author":"JL Cummings","year":"2022","unstructured":"Cummings JL, Devanand D, Stahl SM (2022) Dementia-related psychosis and the potential role for pimavanserin. CNS Spectr 27(1):7\u201315","journal-title":"CNS Spectr"},{"issue":"1","key":"5097_CR97","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1111\/jnc.15509","volume":"162","author":"U Kozlowska","year":"2022","unstructured":"Kozlowska U et al (2022) From psychiatry to neurology: psychedelics as prospective therapeutics for neurodegenerative disorders. J Neurochem 162(1):89\u2013108","journal-title":"J Neurochem"},{"key":"5097_CR98","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2022.109166","volume":"215","author":"EA Schindler","year":"2022","unstructured":"Schindler EA (2022) Psychedelics as preventive treatment in headache and chronic pain disorders. Neuropharmacology 215:109166","journal-title":"Neuropharmacology"},{"key":"5097_CR99","doi-asserted-by":"publisher","first-page":"1326815","DOI":"10.3389\/fphar.2023.1326815","volume":"14","author":"N Freidel","year":"2024","unstructured":"Freidel N et al (2024) Psychedelics, epilepsy, and seizures: a review. Front Pharmacol 14:1326815","journal-title":"Front Pharmacol"},{"issue":"10","key":"5097_CR100","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1089\/jpm.2022.0604","volume":"26","author":"ND Gold","year":"2023","unstructured":"Gold ND et al (2023) Exploring the potential utility of psychedelic therapy for patients with amyotrophic lateral sclerosis. J Palliat Med 26(10):1408\u20131418","journal-title":"J Palliat Med"},{"issue":"2","key":"5097_CR101","doi-asserted-by":"publisher","first-page":"101","DOI":"10.2174\/1874473708666150107120011","volume":"7","author":"M Winkelman","year":"2014","unstructured":"Winkelman M (2014) Psychedelics as medicines for substance abuse rehabilitation: evaluating treatments with LSD, peyote, ibogaine and Ayahuasca. Curr Drug Abuse Rev 7(2):101\u2013116","journal-title":"Curr Drug Abuse Rev"}],"container-title":["Molecular Neurobiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-025-05097-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12035-025-05097-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-025-05097-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T08:07:14Z","timestamp":1759997234000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12035-025-05097-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,4]]},"references-count":101,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["5097"],"URL":"https:\/\/doi.org\/10.1007\/s12035-025-05097-9","relation":{},"ISSN":["0893-7648","1559-1182"],"issn-type":[{"value":"0893-7648","type":"print"},{"value":"1559-1182","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,4]]},"assertion":[{"value":"18 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval and Consent to Participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}